טוען...
Pegvisomant in acromegaly: an update
BACKGROUND: In 2007, we published an opinion document to review the role of pegvisomant (PEG) in the treatment of acromegaly. Since then, new evidence emerged on the biochemical and clinical effects of PEG and on its long-term efficacy and safety. AIM: We here reviewed the emerging aspects of the us...
שמור ב:
| הוצא לאור ב: | J Endocrinol Invest |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer International Publishing
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5443862/ https://ncbi.nlm.nih.gov/pubmed/28176221 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40618-017-0614-1 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|